Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBPNASDAQ:IMNMNASDAQ:NLTXNASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$23.27-1.5%$20.41$15.47▼$36.37$796.14M1.26201,868 shs441,320 shsIMNMImmunome$9.20-6.0%$8.22$5.15▼$16.81$851.85M1.94921,617 shs1.26 million shsNLTXNeoleukin Therapeutics$20.40-2.5%$15.59$2.03▼$14.36$191.72M1.1150,104 shs151,561 shsPHARPharming Group$10.87-6.0%$9.63$6.65▼$12.61$739.57M0.026,264 shs3,787 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-1.52%-1.06%+24.11%+10.81%+24.71%IMNMImmunome-6.03%+0.77%+15.43%+4.90%-42.50%NLTXNeoleukin Therapeutics-2.49%-10.99%+31.53%+22.16%-45.13%PHARPharming Group-9.14%-8.96%+18.81%+23.96%+31.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVBPArriVent BioPharma1.4783 of 5 stars3.60.00.00.03.10.80.0IMNMImmunome1.6388 of 5 stars3.50.00.00.02.32.50.0NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APHARPharming Group2.1572 of 5 stars3.53.00.00.02.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.14Buy$39.2968.83% UpsideIMNMImmunome 3.00Buy$23.33153.62% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/APHARPharming Group 3.00Buy$30.00175.96% UpsideCurrent Analyst Ratings BreakdownLatest NLTX, PHAR, IMNM, and AVBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025AVBPArriVent BioPharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.005/14/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.004/2/2025IMNMImmunomeLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/20/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.003/20/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.003/20/2025IMNMImmunomeStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.003/20/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $25.003/20/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.003/19/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/14/2025PHARPharming GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $39.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A($4.79) per shareN/AIMNMImmunome$10.94M73.19N/AN/A$2.77 per share3.32NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/APHARPharming Group$320.71M2.31$0.12 per share91.82$3.26 per share3.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$69.33M-$3.77N/AN/AN/AN/A-43.89%-29.67%8/13/2025 (Estimated)IMNMImmunome-$106.81M-$3.18N/AN/AN/A-3,014.59%-48.63%-41.62%8/11/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/APHARPharming Group-$10.55M-$0.20N/A362.37N/A-6.09%-7.65%-3.82%7/30/2025 (Estimated)Latest NLTX, PHAR, IMNM, and AVBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AVBPArriVent BioPharma-$0.66-$1.90-$1.24-$1.90N/AN/A5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A19.2819.28IMNMImmunomeN/A6.176.17NLTXNeoleukin TherapeuticsN/A15.3315.33PHARPharming Group0.413.532.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%IMNMImmunome44.58%NLTXNeoleukin Therapeutics52.37%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma18.58%IMNMImmunome8.60%NLTXNeoleukin Therapeutics1.58%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4034.21 millionN/AN/AIMNMImmunome4087.01 million72.92 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataPHARPharming Group28068.03 million66.62 millionNot OptionableNLTX, PHAR, IMNM, and AVBP HeadlinesRecent News About These CompaniesShort Interest in Pharming Group (NASDAQ:PHAR) Expands By 169.2%June 13 at 7:24 PM | marketbeat.comEuropean Penny Stocks Under €200M Market Cap To WatchJune 13 at 10:55 AM | uk.finance.yahoo.comPharming Group (NASDAQ:PHAR) Trading 3.9% Higher - Here's What HappenedJune 12 at 1:20 PM | marketbeat.comPharming Group reports on results of the 2025 Annual General Meeting of ShareholdersJune 11 at 3:52 PM | finance.yahoo.comPharming Group Announces Key Board Appointments and Approvals at 2025 AGMJune 11 at 12:31 PM | tipranks.comPharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Here's WhyJune 11 at 12:31 PM | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Down 4.6% - Here's What HappenedJune 10, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Trading Up 6.7% - Here's WhyJune 8, 2025 | americanbankingnews.comPharming Group (NASDAQ:PHAR) Stock Price Up 6.7% - Here's What HappenedJune 6, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?June 5, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Up - Here's What HappenedJune 4, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Reaches New 1-Year High - What's Next?June 3, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Large Decline in Short InterestJune 3, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Stock Price Up 10.1% - Here's What HappenedMay 31, 2025 | marketbeat.comPharming Group to participate in June investor conferencesMay 28, 2025 | finance.yahoo.comPharming Group to participate in June investor conferences | PHARM Stock NewsMay 28, 2025 | gurufocus.comPharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)May 10, 2025 | finance.yahoo.comPharming Group N.V. (PHAR) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comPharming Group N.V. 2025 Q1 - Results - Earnings Call PresentationMay 9, 2025 | seekingalpha.comPharming Group’s Strong Financial Performance and Strategic Growth Drive Buy RatingMay 8, 2025 | tipranks.comPharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business updateMay 8, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueThese Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioEli Lilly : A Breakout Biotech Powerhouse With Room to RunBy Jeffrey Neal Johnson | May 29, 2025View Eli Lilly : A Breakout Biotech Powerhouse With Room to RunAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksNLTX, PHAR, IMNM, and AVBP Company DescriptionsArriVent BioPharma NASDAQ:AVBP$23.27 -0.36 (-1.52%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$23.26 -0.02 (-0.06%) As of 06/13/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Immunome NASDAQ:IMNM$9.20 -0.59 (-6.03%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.38 +0.18 (+1.90%) As of 06/13/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Neoleukin Therapeutics NASDAQ:NLTX$20.40 -0.52 (-2.49%) As of 06/12/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Pharming Group NASDAQ:PHAR$10.87 -0.69 (-5.97%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
